Clinical Trials Logo

Filter by:
NCT ID: NCT05049200 Completed - COVID-19 Clinical Trials

Characteristics of Weaning From Mechanical Ventilation in COVID-19

Start date: April 1, 2020
Study type: Observational [Patient Registry]

This report is a multicenter, observational, analytical and prospective study. The objective was to describe the weaning of mechanical ventilation in patients with SARS-CoV-2 and the clinical results according to the different types of weaning.

NCT ID: NCT05047263 Not yet recruiting - Clinical trials for Non-diabetic Chronic Kidney Disease

A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease

Start date: September 21, 2021
Phase: Phase 3
Study type: Interventional

Researchers are looking for a better way to treat people who have non-diabetic chronic kidney disease (non-diabetic CKD). The trial treatment, finerenone, is being developed to help people who have long lasting kidney disease, also known as chronic kidney disease (CKD). It works by blocking a certain hormone called aldosterone that causes injury and inflammation in the heart and kidney which is known to play a role in CKD. In this trial, the researchers want to learn if finerenone helps to slow down the worsening of the participants' non-diabetic CKD compared to a placebo. A placebo looks like a trial treatment but does not have any medicine in it. The trial will include about 1,580 men and women who are at least 18 years old. The participants will take finerenone or a placebo once a day as tablets by mouth. All of the participants will also continue to take their current medicine for their CKD. The participants will be in the trial for up to about 50 months. During the trial, the doctors will collect blood and urine samples and check the participants' health. The participants will also answer questions about how they are feeling and what adverse events they are having. An adverse event is a medical problem that happens during the trial. Doctors keep track of all adverse events that happen in trials, even if they do not think the adverse events might be related to the trial treatments.

NCT ID: NCT05043090 Not yet recruiting - Clinical trials for Papillary Renal Cell Carcinoma

Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC

Start date: October 8, 2021
Phase: Phase 3
Study type: Interventional

A clinical trial to compare the effectiveness of savolitinib plus durvalumab versus sunitinib in MET-driven (hepatocyte growth factor receptor), unresectable and locally advanced or metastatic PRCC (Papillary Renal Cell Carcinoma)

NCT ID: NCT05037929 Not yet recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease

A Study to Evaluate the Efficacy and Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease

Start date: September 1, 2021
Phase: Phase 2
Study type: Interventional

This study will evaluate the efficacy, safety, and pharmacokinetics of astegolimab in combination with standard of care chronic obstructive pulmonary disease (COPD) maintenance therapy in patients with COPD who are former or current smokers and have a history of frequent exacerbations.

NCT ID: NCT05034458 Recruiting - Crohn's Disease Clinical Trials

Diet in Pediatric Crohn´s Disease Treated With Biologics

Start date: May 14, 2021
Phase: N/A
Study type: Interventional

Cded in remission patients with high calprotectin

NCT ID: NCT05027672 Active, not recruiting - COVID-19 Vaccines Clinical Trials

Strategies for Combining the First Component of Sputnik V With Other Adenoviral or mRNA-based Vaccines.

Start date: July 30, 2021
Phase: Phase 2
Study type: Interventional

To determine whether a heterologous vaccination regimen in individuals with no known previous history of COVID-19 is non-inferior to that observed with counterpart regimens currently in use in Argentina among persons aged 21 to 65 years

NCT ID: NCT05021835 Not yet recruiting - Inflammation Clinical Trials

ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation

Start date: September 1, 2021
Phase: Phase 3
Study type: Interventional

This study is conducted to see if ziltivekimab reduces the risk of having cardiovascular events (for example heart attack and stroke) in people with cardiovascular disease, chronic kidney disease and inflammation. Participants will either get ziltivekimab (active medicine) or placebo (a dummy medicine which has no effect on the body). This is known as the study medicine. Which treatment participants get is decided by chance. Participants chance of getting ziltivekimab or placebo is the same. Ziltivekimab is not yet approved in any country or region in the world. It is a new medicine doctors cannot prescribe. Participants will get the study medicine in a pre filled syringe. Participants will need to use the pre filled syringe to inject the study medicine into a skinfold once-monthly. The study is expected to last for up to 4 years. Participants will have up to 20 clinic visits. Participants will have blood and urine samples taken at most of the clinic visits. Participants will have their heart examined using sound waves (echocardiography) and electrodes (electrocardiogram). Women cannot take part if pregnant, breast-feeding or planning to get pregnant during the study period.

NCT ID: NCT05011513 Recruiting - COVID-19 Clinical Trials

A Study of PF-07321332/Ritonavir in Non-hospitalized Low-Risk Adult Participants With COVID-19

Start date: August 25, 2021
Phase: Phase 3
Study type: Interventional

The primary hypothesis to be tested is whether or not there is a difference in time to sustained alleviation of all targeted COVID-19 signs and symptoms through Day 28 between PF-07321332/ritonavir and placebo.

NCT ID: NCT05007080 Not yet recruiting - Healthy Clinical Trials

A Study to Evaluate Different Dose Levels of Ad26.COV2.S in Healthy Adolescents From 12 to 17 Years Inclusive

Start date: September 23, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

The primary purpose of this study is to assess the safety, reactogenicity, and humoral immune response of Ad26.COV2.S or placebo administered intramuscularly (IM) as a 1-dose schedule or as a 2-dose schedule (56-day interval) in adolescents (Part 1 and Part 2); and to demonstrate non-inferiority (NI) of immune responses induced by 1 dose or 2 doses or of a lower, to be determined, dose level of Ad26.COV2.S in adolescents versus 1 or 2 doses of Ad26.COV2.S in young adults (Part 2).

NCT ID: NCT05006573 Recruiting - Clinical trials for Non-cystic Fibrosis Bronchiectasis

Efficacy and Safety of Benralizumab in Patients With Non-cystic Fibrosis Bronchiectasis

Start date: July 21, 2021
Phase: Phase 3
Study type: Interventional

This is a multicentre, randomised, double-blind, parallel-group, placebo-controlled, 52 week Phase III study to test the hypothesis that benralizumab will reduce exacerbation rates compared with placebo on top of standard-of-care therapy in adult patients with non-cystic fibrosis bronchiectasis with eosinophilic inflammation (NCFB+EI). All patients who complete the 52-week double-blind treatment period on investigational product (IP) may be eligible to continue into an open-label extension (OLE), during which all patients will receive benralizumab. The OLE treatment period is intended to allow patients at least one year of treatment with open label benralizumab.